컴퓨젠 (CGEN) 주가

컴퓨젠(CGEN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.47 (+0.41%), 시가총액 $0.26B, PER (주가수익비율) 7.24, 52주 최저~최고 $1.33 ~ $3.10.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck s

핵심 지표

• 현재가: $2.47 (+0.41%)
• 시가총액: $0.26B
• PER (주가수익비율): 7.24
• 52주 최저~최고: $1.33 ~ $3.10
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

컴퓨젠의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

컴퓨젠 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 2.66
• 순이익률: 0.49%
• 영업이익률: 0.83%

자주 묻는 질문